<DOC>
	<DOCNO>NCT00022893</DOCNO>
	<brief_summary>The purpose study enable retreatment Iodine-131 Anti-B1 Antibody therapy patient non-Hodgkin 's lymphoma ( NHL ) previously respond ( PR , CCR , CR ) least 3 month Iodine-131 Anti-B1 Antibody therapy .</brief_summary>
	<brief_title>Safety Efficacy Study Iodine-131 Anti-B1 Antibody Retreatment Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>The endpoint study determine response rate , complete response rate , duration response , time progression , time-to-treatment failure , safety , survival follow Iodine-131 Anti-B1 Antibody therapy patient NHL previously respond ( PR , CCR , CR ) duration response least 3 month Iodine-131 Anti-B1 Antibody therapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>Patients must histologically confirm initial diagnosis nonHodgkin 's Bcell lymphoma . Patients must previously respond ( PR , CCR , CR ) duration response least 3 month Iodine131 AntiB1 Antibody therapy . The patient 's disease must progress follow response Iodine131 AntiB1 Antibody therapy . Patients must evidence tumor tissue express CD20 antigen . Patients must performance status least 60 % Karnofsky Scale anticipate survival least 3 month . Patients must absolute granulocyte count ( ANC ) &gt; 1,500 cells/mm3 ( US ) &gt; 1,500 x 109/l ( UK ) platelet count &gt; 100,000 cells/mm3 ( US ) &gt; 100,000 x 109/l ( UK ) within 14 day study entry . These blood count must sustain without support hematopoietic cytokine transfusion blood product . Patients must adequate renal function ( define serum creatinine &lt; 1.5 x upper limit normal ) hepatic function ( defined total bilirubin &lt; 1.5 x upper limit normal hepatic transaminase [ AST ALT ] &lt; 5 x upper limit normal ) within 14 day study entry . Patients must bidimensionally measurable disease . At least one lesion must great equal 2 x 2 cm ( CT scan ) . Patients average 25 % intratrabecular marrow space involve lymphoma bone marrow biopsy specimen assess microscopically within 42 day study entry . Bilateral posterior iliac crest core biopsy require percentage intratrabecular space involve exceed 10 % unilateral biopsy . The mean bilateral biopsy must 25 % . Patients receive cytotoxic chemotherapy , radiation therapy , immunosuppressant , cytokine treatment within 4 week prior study entry ( 6 week nitrosourea compound ) exhibit persistent clinical evidence toxicity . The use systemic steroid must discontinue least 1 week prior study entry . Patients active obstructive hydronephrosis . Patients evidence active infection require IV antibiotic time study entry . Patients New York Heart Association class III IV heart disease serious illness would preclude evaluation . Patients prior malignancy lymphoma , except adequately treated skin cancer , situ cervical cancer , cancer patient diseasefree 5 year . Patients diseasefree another cancer great 5 year must carefully assessed time study entry rule recurrent disease . Patients know HIV infection . Patients know brain leptomeningeal metastasis . Patients pregnant nursing ( breastfeed ) . Patients childbearing potential must undergo serum pregnancy test within 7 day prior study entry . Males female must agree use effective contraception 6 month follow treatment . Patients previous allergic reaction iodine . This include react IV iodinecontaining contrast material . Patients progressive disease within 1 year irradiation arise field previously irradiate &gt; 3500 cGy . Patients become HAMA positive follow Iodine131 AntiB1 Antibody therapy patient HAMA positive time enrollment . Patients concurrently receive either approve nonapproved ( another protocol ) anticancer drug biologics .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Radioimmunotherapy</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Corixa</keyword>
	<keyword>Bexxar</keyword>
	<keyword>Anti-B1 Antibody</keyword>
	<keyword>Tositumomab</keyword>
	<keyword>Iodine -131 Anti-B1 Antibody</keyword>
	<keyword>Iodine I 131 Tositumomab</keyword>
</DOC>